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Introduction. Concern regarding overtreatment of prostate cancer (CaP) is leading to increased attention on active surveillance
(AS).This studyexamined CaPsurvivors onASand compared secondary treatment patterns and overall survival by race/ethnicity.
Methods. The study population consisted of CaP patients self-classiﬁed as black or white followed on AS in the Center for
Prostate Disease Research (CPDR) multicenter national database between 1989 and 2008. Secondary treatment included radical
prostatectomy (RP), external beam radiation therapy or brachytherapy (EBRT-Br), and hormone therapy (HT). Secondary
treatment patterns and overall survival were compared by race/ethnicity. Results. Among 886 eligible patients, 21% were black.
Despite racial diﬀerences in risk characteristics and secondary treatment patterns, overall survival was comparable across race. RP
following AS was associated with the longest overall survival. Conclusion. Racial disparity in overall survival was not observed in
this military health care beneﬁciary cohort with an equal access to health care.
1.Introduction
Racial/ethnic disparity in cancer outcomes has been exten-
sively studied. With respect to prostate cancer (CaP), poorer
patient outcomes among black men have been attributed
to more advanced disease at the time of detection, less
aggressive initial treatment, lower socioeconomic status
(SES), inadequate quality and access to care, and/or more
aggressive biology of the disease [1–14]. However, not
all studies indicate that disparities exist. A recent meta-
analysis concluded that there were no diﬀerences in CaP-
speciﬁc or overall survival for white versus black men after
accounting for methodological ﬂaws of individual studies
[15]. Similarly, when examining the accuracy of Partin tables
for black men, Heath et al. found that race was not an
independent prognostic factor for CaP progression despite
higher grade and prostate-speciﬁc antigen (PSA) levels at
baseline for black men [16]. Additional research has shown
t h a to n c ef a c t o r ss u c ha sS E Sa n dt r e a t m e n tp a t t e r n sa r e
taken into account, observed racial disparities disappear
[7, 12].
Growing concern regarding overtreatment of CaP is
leading to increased interest in active surveillance (AS) as an
option for patients with “low” or “very low” risk CaP. The
National Comprehensive Cancer Network recommends AS
for patients with “very low risk” CaP and a life expectancy
of less than 20 years or men with a life expectancy of less
than 10 years whose cancers are considered “low risk” [17].
The clinical dilemma becomes discerning if, and when, to
intervene with secondary treatment. Factors that determine
whether CaP is low, intermediate, or high risk include PSA
at time of diagnosis, biopsy Gleason sum, and clinical stage
at time of presentation [18]. Therefore, with the growing
interest and clinical use of AS, the goal of this study was to2 Prostate Cancer
assess whether or not this practice carries similar risk among
racial/ethnic groups.
Given the possibility that survival disparities may be a
consequence of treatment modality, we examined secondary
treatment patterns during the survivorship period within
a cohort of patients initially followed on AS to determine
whether there are diﬀerences across race/ethnicity in the
following endpoints: (1) secondary treatment patterns, (2)
overall survival.
2. Methods
2.1. Study Population. The study population was comprised
of men enrolled in the institutional review board (IRB)-
approved Center for Prostate Disease Research (CPDR)
multicenter national database. A description of this cohort
and related data collection activities has been described
previously [19, 20]. The study sample was restricted to
patients diagnosed with CaP between January 1, 1989, and
December 31, 2008, and for whom initial treatment was AS.
For the purposes of this study, AS was deﬁned as the absence
oftreatmentwithcurativeintentforaminimumof9months
following CaP diagnosis. Therefore, the study sample was
restricted to patients with at least 9-month followup after
CaP diagnosis in order to deﬁne primary treatment as AS.
Only white and black patients were analyzed because of
inadequatesamplesizesinotherracial/ethniccategories.Sec-
ondary treatment was categorized in the following manner:
thosewhocontinuedASuntiltheendofthestudyperiod(no
secondary treatment); radical prostatectomy (RP); external
beam radiation therapy or brachytherapy (EBRT-Br); or
hormone therapy (HT) after 9 months on AS.
2.2. Demographics and Clinical Characteristics. As part of
routine data collection activities of the CPDR multicenter
national database, the following demographic and clinical
data were recorded for each subject: age at CaP diagnosis,
self-reported race (i.e., white, black), PSA at diagnosis (cat-
egorized as <10, 10–19.99, and ≥20ng/mL), clinical T stage
(T1-T2a, T2b, T2c, and T3-4), biopsy Gleason sum (2–6, 7,
8–10), number of comorbidities (categorized as 0, 1, 2, 3+),
secondarytreatmenttype(categorizedasnone,RP,EBRT-Br,
and HT), and dates of medical services. Risk strata were esti-
mated using the criteria of D’Amico et al [18]. This approach
combines diagnostic PSA, clinical T stage, and biopsy grade
into a single composite index in order to classify men into
low-, intermediate-, and high-risk disease. This classiﬁcation
schema has been described previously [18]. In brief, low-
risk patients are deﬁned as those with the following clinical
characteristics: clinical stage T1c or T2a; PSA ≤ 10ng/mL;
Gleason score ≤6. Intermediate risk patients are classiﬁed as
those with clinical stage T2b; or Gleason = 7; or PSA > 10
and ≤20ng/mL. Finally, high risk patients are those with
clinicalstageT2c;orPSA > 20ng/mL;orGleasonscore8–10.
2.3. Study Endpoints. The primary study endpoint was over-
all survival. As part of data abstraction, vital status was re-
viewed annually as part of ongoing patient followup. Patient
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Figure 1: Kaplan Meier unadjusted estimation curve for time to
secondary treatment stratiﬁed by race among subjects with prostate
cancer (CaP) followed on active surveillance (AS) for primary
treatment (N = 886).
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Figure 2: Kaplan Meier unadjusted estimation curve for overall
survival stratiﬁed by secondary treatment type among subjects
with prostate cancer (CaP) followed on active surveillance (AS) for
primary treatment (N = 886).
vital status was conﬁrmed by searching the national death
index using social security number, birth date, and name of
the patient at the medical center where he was consented and
enrolled into the database study. A secondary study endpoint
included time to secondary treatment, which was calculated
as the time from diagnosis with CaP to the time of initiation
of RP, EBRT-Br, or HT. For patients who did not receiveProstate Cancer 3
Table 1: Characteristics of subjects with prostate cancer (CaP) followed on active surveillance (AS) for primary treatment, stratiﬁed by race
(N = 886).
Race characteristic Total White Black P value
N = 886 n = 696 n = 190
Age at diagnosis, years <0.0001
Mean (±SD)1 69.3 (±8.4) 70.4 (±8.1) 65.3 (±8.4)
Median (range) 70.2 (41.3–91.8) 71.7 (41.3–91.8) 65.6 (41.7–85.3)
<60 109 (12.3) 67 (9.6) 42 (22.1)
60–60.9 324 (36.6) 232 (33.3) 92 (48.4)
≥70 453 (51.1) 397 (57.0) 56 (29.5)
PSA at diagnosis, ng/mL, N (%) <0.0001
<10 607 (68.5) 499 (71.7) 108 (56.8)
10–19.99 153 (17.3) 115 (16.5) 38 (20.0)
≥20 126 (14.2) 82 (11.8) 44 (23.2)
Comorbidities, N (%) 0.1793
0 231 (26.1) 187 (26.9) 44 (23.2)
1 264 (29.8) 205 (29.4) 59 (31.0)
2 198 (22.3) 146 (21.0) 52 (27.4)
≥3 193 (21.8) 158 (22.7) 35 (18.4)
Clinical T stage, N (%) 0.1260
T1-T2a 660 (74.5) 520 (74.7) 140 (73.7)
T2b 96 (10.8) 82 (11.8) 14 (7.4)
T2c 68 (7.7) 49 (7.0) 19 (10.0)
T3-4 62 (7.0) 45 (6.5) 17 (8.9)
Biopsy grade, N (%) 0.1806
2–6 646 (72.9) 517 (74.3) 129 (67.9)
7 168 (19.0) 127 (18.2) 41 (21.6)
8–10 72 (8.1) 52 (7.5) 20 (10.5)
D’Amico et al. risk strata, N (%) 0.0023
Low 434 (49.0) 359 (51.6) 75 (39.5)
Intermediate 228 (25.7) 178 (25.6) 50 (26.3)
High 224 (25.3) 159 (22.8) 65 (34.2)
Secondary treatment type, N (%) <0.0001
None (AS only) 401 (45.3) 333 (47.8) 68 (35.8)
RP2 125 (14.1) 87 (12.5) 38 (20.0)
EBRT-Br3 192 (21.7) 134 (19.2) 58 (30.5)
HT4 168 (19.0) 142 (20.4) 26 (13.7)
Time from Dx5 to secondary treatment, months 0.0135
Mean (±SD) 30.6 (±26.6) 32.7 (±28.5) 24.5 (±18.6)
Median (range) 19.6 (9.0–149.6) 20.3 (9.0–149.6) 16.0 (9.0–92.0)
Followup, years 0.4641
Mean (±SD) 6.1 (±4.0) 6.1 (±4.0) 5.8 (±3.7)
Median (range) 5.2 (0.8–17.2) 5.2 (0.8–17.2) 5.4 (0.8–16.8)
1SD: standard deviation.
2RP: radical prostatectomy.
3EBRT-BR: external beam radiation therapy and Brachytherapy, combined.
4HT: hormone therapy.
5Dx: diagnosis of CaP.
secondary treatment, followup time is censored at the end
of the study period.
2.4. Statistical Analysis. Descriptive statistics included mea-
sures of central tendency (i.e., mean, median) as well as
measures of dispersion (i.e., standard deviation (SD) range).
Student t tests were used to compute means in continuous
patient characteristics, included age, PSA at diagnosis, and
followup time. Patient characteristics were computed for the
overall sample, as well as stratiﬁed for race and secondary4 Prostate Cancer
Table 2: Characteristics of subjects with prostate cancer (CaP) followed on active surveillance (AS) for primary treatment, stratiﬁed by
secondary treatment type (N = 886).
Secondary treatment type characteristic None (AS1 only) AS + RP2 AS + EBRT/Br3 AS + HT4
P value
n = 401 n = 125 n = 192 n = 168
Age at diagnosis, years <0.0001
Mean (±SD)5 70.4 (±8.0) 60.7 (±7.9) 69.1 (±7.0) 73.3 (±7.0)
Median 71.7 61.3 69.5 74.4
Range 41.5–91.3 41.3–77.2 48.4–85.5 44.4–91.8
PSA at diagnosis, ng/mL, N (%) <0.0001
<10 322 (80.3) 98 (78.4) 101 (52.6) 86 (51.2)
10–19.9 49 (12.2) 13 (10.4) 51 (26.6) 40 (23.8)
≥20 30 (7.5) 14 (11.2) 40 (20.8) 42 (25.0)
Race, N (%) <0.0001
White 333 (83.0) 87 (69.6) 134 (69.8) 142 (84.5)
Black 68 (17.0) 38 (30.4) 58 (30.2) 26 (15.5)
Comorbidities, N (%) 0.0172
0 106 (26.4) 40 (32.0) 48 (25.0) 37 (22.0)
1 115 (28.7) 40 (32.0) 56 (29.2) 53 (31.6)
2 76 (19.0) 30 (24.0) 55 (28.6) 37 (22.0)
3 or above 104 (25.9) 15 (12.0) 33 (17.2) 41 (24.4)
Clinical T stage, N (%) <0.0001
T1-T2a 330 (82.3) 92 (73.6) 129 (67.2) 109 (64.9)
T2b 38 (9.5) 19 (15.2) 22 (11.5) 17 (10.1)
T2c 21 (5.2) 10 (8.0) 15 (7.8) 22 (13.1)
T3-4 12 (3.0) 4 (3.2) 26 (13.5) 20 (11.9)
Biopsy grade, N (%) <0.0001
2–6 318 (79.3) 99 (79.2) 119 (62.0) 110 (65.5)
7 61 (15.2) 21 (16.8) 47(24.5) 39 (23.2)
8–10 22 (5.5) 5 (4.0) 26 (13.5) 19 (11.3)
D’Amico et al. risk strata <0.0001
Low 246 (61.4) 68 (54.4) 61 (31.8) 59 (35.1)
Intermediate 93 (23.2) 33 (26.4) 56 (29.2) 46 (27.4)
High 62 (15.5) 24 (19.2) 75 (39.1) 63 (37.5)
Time from Dx6 to secondary treatment, months <0.0001
Mean (±SD5) — 21.8 (±18.7) 25.7 (±21.3) 42.8 (±32.1)
Median — 14.0 16.7 34.8
Range — 9.0–121.2 9.0–115.0 9.2–149.6
Followup, years <0.0001
Mean (±SD5)4 . 2 ( ±3.1) 7.6 (±4.3) 7.2 (±3.9) 7.9 (±3.8)
Median 3.4 7.4 6.4 7.5
Range 0.7–16.5 0.8–17.2 0.8–17.0 0.9–17.2
1AS: active surveillance.
2RP: radical prostatectomy.
3EBRT-BR: external beam radiation therapy and Brachytherapy, combined.
4HT: hormone therapy.
5SD: standard deviation.
6Dx: diagnosis of CaP.
treatment type. Mantel Haenszel chi-square tests were used
to compare distributions of categorical variables by race and
secondary treatment type.
Kaplan Meier (KM) unadjusted estimation curves were
plotted to examine the relationships between (1) race and
secondary treatment and (2) race and overall survival. KM
estimation was also used to examine potential statistical
interactionbetweenraceandsecondarytreatmentinpredict-
ing overall survival patterns by producing a single KM curve
for each racial group. Overall survival was then stratiﬁed by
secondary treatment type.
Multivariable Cox proportional hazards modeling was
used to examine overall survival, controlling for key demo-
graphics and clinical characteristics. A stratiﬁed analysisProstate Cancer 5
was then conducted to examine possible eﬀect modiﬁcation
between race and secondary treatment stratum (N = 4) with
time to overall survival as the dependent outcome. Hazard
odds ratio (HOR) eﬀect estimates and corresponding 95%
conﬁdence intervals (CI) are reported. All statistical tests are
2 sided (summary alpha = 0.05), and the decision rule was
based on value < 0.05. All statistical analysis was performed
using SAS 9.2 (SAS Institute Inc., Cary, NC).
3. Results
Descriptive characteristics of the study sample are summa-
rized in Tables 1 and 2, stratiﬁed for race/ethnicity and
secondary treatment type, respectively. There were a total
of 886 eligible patients. Twenty-one percent of the sample
was black. Median age, time to secondary treatment, and
followup time were 70.2, 19.6 months (1.6 years), and 5.2
years,respectively.Overtwo-thirdsofpatientshaddiagnostic
PSA values < 10ng/mL. Almost three-quarters of subjects
(74%) had at least one comorbid condition at time of CaP
diagnosis. Three-quarters of patients had clinical stage T1-
T2a disease (74.8%). Biopsy Gleason sum was 2–6 for 73%
of subjects. More than half of the study sample (51%) was
≥70 years of age, yet almost half (45.3%) continued AS for
primarytreatmentthroughoutthestudyperiod.ByD’Amico
et al. risk strata, almost half of the patients were considered
low risk (49.0%), while more than a quarter of patients
(25.7%) were intermediate and high risk (25.3%) at time
of CaP detection. For those receiving secondary treatment,
14.1% had RP, 21.7% had EBRT-Br, and 19.0% had HT.
Bivariate comparisons of sample characteristics across
race demonstrate important diﬀerences (Table 1). Black men
had a signiﬁcantly younger mean age at CaP diagnosis (65.3
versus 70.4 years; P<0.0001), a greater proportion of diag-
nostic PSA ≥ 10 (43.2% versus 28.3%; P<0.0001), a greater
proportion of high-risk disease (34.2% versus 22.8%; P =
0.0023), and a greater proportion of secondary treatment by
RPorEBRT-Brcombined(50.5%versus31.7%;P<0.0001).
Table 2showsbivariatecomparisonsofsamplecharacter-
istics across secondary treatment type. Patients who received
RP were younger with a median age of 61 years, compared
to 72, 70, and 74 years for AS only, EBRT-BR, and HT,
respectively (P<0.0001). Patients who received AS or RP
hadlowermediandiagnosticPSAvaluesthanthosereceiving
EBRT-BR or HT (P<0.0001). Patients who had RP were
also less likely to have multiple comorbidities compared to
the other treatment groups (P = 0.017). The secondary
treatmentgroupswiththemostadverseclinicalfeatureswere
those who went on to receive EBRT-Br and HT (P<0.0001).
Those who continued to receive AS throughout the study
period had a signiﬁcantly shorter median followup time
(P<0.0001). White patients were more likely to continue
using AS than black patients, whereas the latter were more
likely to receive RP or EBRT-Br secondary to AS. Those who
had AS-HT had signiﬁcantly longer intervals between CaP
diagnosis and secondary treatment (median = 35 months or
2.9 years), while those on AS-RP had the shortest interval
(median = 14.9 months or 1.2 years). Interestingly, none of
the black patients who received HT secondary to AS were in
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Figure 3: Kaplan Meier unadjusted estimation curve for overall
survival among white men stratiﬁed by secondary treatment type
among subjects with prostate cancer (CaP) followed on active
surveillance (AS) for primary treatment (n = 696).
the youngest age group (<60 years) as compared to only 4
(6%) white patients. However, the sample of black men in
this treatment stratum was very small (n = 26).
KM unadjusted time-to-event estimation curves are
depicted in Figures 1–4. Time to secondary treatment was
compared across race (Figure 1) revealing no statistically
signiﬁcant diﬀerences for black versus white patients; sur-
vival lines are parallel and roughly superimposed in the ﬁrst
48 months after CaP diagnosis (log rank P = 0.42). Next,
overall survival was examined as a function of secondary
treatment type (Figure 2). This analysis was then repeated
for black (Figure 3) and white (Figure 4) patients separately.
Irrespective of race, a strong survival beneﬁt was observed
for patients receiving RP subsequent to AS versus all other
secondary treatment groups (log rank P<0.0001). In
contrast, patients receiving AS only had the worst survival.
Table 3 provides ﬁndings from multivariable Cox pro-
portional hazards regression analysis predicting over-
all survival. This model shows that age at diagnosis
(HOR(≥70 versus <60) = 1.9, CI = 1.03–3.36, P = 0.041),
risk stratum (HOR(High versus Low) = 2.6, CI = 1.93–3.58, P<
0.0001; HOR(Intermediate versus Low) = 1.60, CI = 1.16–2.24,
P = 0.0042),secondarytreatmenttype(HOR(RP versus None) =
0.022,CI=0.011–0.043, P<0.0001; HOR(EBRT-Br versus None) =
0.052, CI = 0.031–0.087, P<0.0001; HOR(HTversus None) =
0.107, CI = 0.069–0.167, P<0.0001), and time from CaP
diagnosis to secondary treatment (HOR(per month) = 0.97,6 Prostate Cancer
Table 3: Multivariable Cox proportional hazards regression pre-
dicting overall survival in a cohort of subjects with prostate cancer
(CaP) followed on active surveillance (AS) for primary treatment
(N = 886).
Characteristic HOR1 (95% CI2) P value
Age at diagnosis, years 0.1122
<60 Referent —
60–60.9 1.837 (1.016–3.322) 0.0441
≥70 1.856 (1.026–3.357) 0.0408
Race
White Referent —
Black 1.106 (0.805–1.519) 0.5362
Comorbidities 0.2714
0 Referent —
1 1.235 (0.877–1.738) 0.2271
2 1.029 (0.700–1.512) 0.8847
3 or more 1.373 (0.952–1.978) 0.0895
D’Amico et al. risk strata <0.0001
Low Referent —
Intermediate 1.612 (1.162–2.237) 0.0042
High 2.627 (1.927–3.580) <0.0001
Secondary treatment type <0.0001
None (AS only) Referent —
RP3 0.022 (0.011–0.043) <0.0001
EBRT-Br4 0.052 (0.031–0.087) <0.0001
HT5 0.107 (0.069–0.167) <0.0001
Dx6 to secondary treatment,
months 0.970 (0.965–0.976) <0.0001
1HOR: hazard Odds Ratio.
2CI: conﬁdence Interval.
3RP: radical prostatectomy.
4EBRT-BR: external beam radiation therapy and Brachytherapy, combined.
5HT: hormone therapy.
6Dx: diagnosis of CaP.
CI = 0.965–0.976, P<0.0001) were signiﬁcantly associated
with overall survival.
Finally, multivariable Cox proportional hazards analysis
predictingoverallsurvival(Table4)wasconducted,stratiﬁed
on secondary treatment type for a total of four models.
These analyses show that, regardless of secondary treatment
type, no racial disparity in overall survival was observed.
Consistently across all 4 models, a signiﬁcant predictor of
overall survival was the D’Amico et al. risk classiﬁcation. For
three of four groups, this signiﬁcant ﬁnding was restricted
to comparison of risk at the extremes (i.e., high versus low).
For the AS-only stratum, high D’Amico risk was associated
with a 3.5 times increase odds of death from all causes
(HOR(High versus Low) = 3.52, CI = 2.18–5.69, P<0.0001).
Similarly, among the RP secondary treatment stratum, high
D’Amico risk predicted more than a 5.5 increased odds of
death (HOR(High versus Low) = 5.64, CI = 1.48–21.4, P =
0.011); although the magnitude of this point estimate was
large, it was also less precise due to a smaller sample size in
this treatment group. Forthe EBRT-Br group, the risk com-
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Figure 4: Kaplan Meier unadjusted estimation curve for overall
survival among black men stratiﬁed by secondary treatment type
among subjects with prostate cancer (CaP) followed on active
surveillance (AS) for primary treatment (n = 190).
parison at the extremes was associated with over a fourfold
increased odds of death (HOR(High versus Low) = 4.20, CI =
1.98–8.90, P = 0.0002), while that for intermediate versus
lowriskdemonstratedaborderlineeﬀectonsurvival,though
it was not statistically signiﬁcant: HOR(Intermediate versus Low) =
2.16, CI =− 5.3, P = 0.020 (Table 3). Finally, for the
HT secondary treatment stratum, both comparisons of high
versus low risk and intermediate versus low risk were signiﬁ-
cant in predicting overall survival: HOR(High versus Low) = 2.6,
CI = 1.4–4.8, P = 0.0022; HOR(Intermediate versus Low) = 2.3,
CI = 1.2–4.5, P = 0.018, respectively.
Time from diagnosis with CaP to secondary treatment
was also examined in the three relevant treatment groups:
AS-RP, AS-EBRT-Br, and AS-HT. For both EBRT-Br and HT
as secondary treatments, there was a statistically signiﬁcant
eﬀect of this time interval on overall survival such that
shorter time to treatment with curative intent from EBRT-
Br and HT was associated with a slightly greater odds of
deathfromallcauses(HOR(per month) = 0.98,CI = 0.97–1.00,
P = 0.042) and (HOR(per month) = 0.98, CI = 0.98–0.99,
P = 0.0010), respectively.
Multivariable Cox proportional hazards modeling was
also performed stratiﬁed being by race with secondary
treatmentincludedasamodelcovariateinplaceofrace,with
comparable covariates entered into the secondary treatment-
stratiﬁed models. In these 2 race-speciﬁc models, the lowest
odds of death was observed for those who initiated RP
secondary to AS for both black patients (HOR = 0.063, CI =
0.014–0.29, P = 0.0004) and white patients (HOR = 0.26,Prostate Cancer 7
Table 4:MultivariableCoxproportionalhazardsmodelpredictingoverallsurvivalinacohortofsubjectswithprostatecancer(CaP)followed
on active surveillance (AS) for primary treatment, stratiﬁed by secondary treatment type.
Secondary treatment type
characteristic
None (AS only) RP3 EBRT-Br4 HT5
HOR1
(95% CI2) P value HOR (95%
CI) P value HOR (95%
CI) P value HOR (95%
CI) P value
Age at diagnosis, years 0.1737 0.1532 0.3743 0.4236
<60 Referent — Referent — Referent — Referent —
60–60.9 2.43
(0.84–6.97) 0.0983 1.65
(0.35–7.60) 0.5196 1.35
(0.45–4.02) 0.5836 1.84
(0.40–8.27) 0.4264
≥70 2.700
(0.95–7.64) 0.0616 4.41
(0.85–22.7) 0.0762 1.84
(0.62–5.42) 0.2663 1.32
(0.30–5.74) 0.7108
Race
White Referent — Referent — Referent — Referent —
Black 1.24
(0.74–2.07) 0.4120 0.46
(0.09–2.32) 0.3522 1.14
(0.64–2.03) 0.6478 1.17
(0.60–2.29) 0.6282
Comorbidities 0.3218 0.4464 0.0061 0.5145
0 Referent — Referent — Referent — Referent —
1 1.15
(0.66–1.99) 0.6059 2.42
(0.65–8.99) 0.1865 0.58
(0.27–1.23) 0.1582 1.06
(0.53–2.12) 0.8657
2 1.60
(0.85–3.02) 0.1425 0.97
(0.19–4.84) 0.9731 0.48
(0.21–1.06) 0.0724 1.22
(0.60–2.46) 0.5730
≥3 1.53
(0.86–2.71) 0.1431 2.05
(0.33–12.6) 0.4361 1.70
(0.82–3.53) 0.1518 0.71
(0.34–1.50) 0.3800
D’Amico et al. risk strata <0.0001 0.0353 0.0007 0.0787
Low Referent — Referent — Referent — Referent —
Intermediate 1.47
(0.88–2.45) 0.1371 1.78
(0.44–7.12) 0.4124 2.16
(0.99–4.71) 0.0528 1.75
(0.87–3.51) 0.1112
High 3.52
(2.18–5.69) <0.0001 5.64
(1.48–21.4) 0.0110 4.20
(1.98–8.90) 0.0002 2.03
(1.09–3.78) 0.0257
Dx6 to secondary
treatment, months —— 1.00
(0.97–1.03) 0.8635 0.98
(0.97–1.00) 0.0424 0.98
(0.975–0.99) 0.0010
1HOR: hazard Odds Ratio.
2CI: conﬁdence Interval.
3RP: radical prostatectomy.
4EBRT-BR: external beam radiation therapy and Brachytherapy, combined.
5HT: hormone therapy.
6Dx: diagnosis of CaP.
CI = 0.14–0.46, P<0.0001); this eﬀect was more pro-
nounced in black patients (data not shown).
4. Discussion
Being black was not a predictor of poorer overall survival
among participants of the CPDR multicenter national
database undergoing AS as initial followup for CaP. This
ﬁnding was evident despite clear racial diﬀerences in clin-
ical characteristics at time of CaP detection. Speciﬁcally,
black men were observed to have a greater proportion of
intermediate- and high-risk disease, but this ﬁnding did
not translate into longer-term adverse outcomes in terms of
overall survival.
Interestingly, for men who underwent secondary treat-
ment, a striking beneﬁt was observed among the group who
received RP when controlling for key clinical characteristics.
Men who remained on AS had the worst survival, despite
controlling for baseline risk characteristics. This is especially
striking given that these patients had the shortest median
followup time of only 3.4 years. This may be explained,
in part, by reduced intervention with additional treatments
among patients for whom death seems imminent. This is
supported by the ﬁnding that patients who remained on AS,
only,weremorelikelytohave3ormorecomorbidconditions
at time of CaP diagnosis.
Racialdisparityinoutcomesforprostatecancersurvivors
has been observed in several national data sources [7, 14,
21, 22]. In contrast, a recent meta-analysis concluded that
there were no diﬀerences in overall or CaP-speciﬁc mortality
for black versus white men with CaP [15]. Where racial
diﬀerences have been noted, some researchers have proposed
thatvariationintreatmentpatternsforCaPcanbelinkedtoa
man’sSESwhichinturn,maybepartlytoblameforobserved
racial disparities [4, 5, 9, 12].
Another possible explanation for racial disparity in CaP
outcomes may be the geographical location or institution
where health care services are received. Onega et al. found8 Prostate Cancer
that higher overall mortality among black versus white
Medicare beneﬁciaries was no longer signiﬁcant when
restricting analysis to location of services at the National
Cancer Institute cancer centers. This ﬁnding lends support
to the concept that place of services may, in part, account for
observed racial diﬀerences [10].
Using the Detroit Surveillance, Epidemiology, and End
Results data, Powell et al. found larger average tumor
v ol umesinblac kv ersuswhit emenaft erRPasw ellasa4-fold
ratio of distant disease among black versus white men. The
authors conclude that these ﬁndings may indicate biological
diﬀerences in disease progression [11].
In 2003, an Institute of Medicine report dedicated to the
topic of unequal treatment in health care in the United States
found that clear and striking diﬀerences exist in the receipt
of services by race/ethnicity [23]. Other researchers have
noted inequity in quality and type of care by race/ethnicity
as a potentially contributing cause of disparities in CaP and
overall survival [2, 6].
In an examination of CaP patients of African ancestry
from New York, Guyana, and the Republic of Tobago and
Trinidad, Mutetwa et al. found sharp survival rate disparity
between Caribbean-born men diagnosed with CaP versus
New York residents. However, immigrant Caribbean-born
men had survival rates that approximated those of men
from New York [8]. These ﬁndings argue for the importance
of environmental factors in inﬂuencing outcomes for CaP
survivors. This ﬁnding could include early detection of CaP,
SES and receipt of treatment, location of health care services,
and other factors not yet elucidated. When examining
the interrelationships between race, SES, and treatment,
Schwartz et al. found that much of the survival disadvantage
for black men could be explained by a combination of low
SES and receipt of nonsurgical treatment for disease [12].
In our study, we examined military health care beneﬁcia-
riesparticipatingintheCPDRmulticenternationaldatabase.
Patients in the CPDR database study constitute a screened
cohort with regular PSAs and digital rectal examinations, in
conjunction with annual physical examination beginning at
age 40. Therefore, lack of racial/ethnic disparity in overall
survival in this study sample may be, in part, attributable
to accessibility to health care services. In the face of poorer
baseline risk proﬁles among our black subjects, the observa-
tion of comparable survival outcomes may be explained by
the shorter time to secondary treatment among black men,
coupled with the preferential choice of RP secondary to AS
among black. This explanation is consistent with our ﬁnding
that the best overall survival was observed among men who
received RP after AS.
4.1. Study Considerations. Despite important work that
underscores the importance of SES in the relationship
between race and survival, the CPDR does not systematically
collect data on income or education. The closest correlation
of SES in the CPDR cohort would be a patient’s military
rank, which was not available for this study. Albeit, patients
included in this study are those eligible for military health
care regardless of their education, income, or region of the
country in which they receive services. While SES cannot be
ruled as out as an explanatory factor in the absence of racial
disparities in this cohort, we believe there is relative homo-
geneity with respect to SES in our cohort regardless of race.
A clear advantage to this study is the proportion of
black men included. The CPDR database has an over-
representation of black men—roughly 20%—compared to
a 2010 national average of 13.5% [24]. As mentioned, we
could not examine other racial/ethnic minorities such as
Asian/Paciﬁc Islanders and Hispanics as sample sizes because
these groups are not large enough in the CPDR database to
model the study endpoints of interest.
The key strengths of this study are the CPDR multicenter
national database cohort itself, which contains a large
proportionofblackpatients.Also,thiscohortiscoupledwith
long-term followup of its enrollees and strong adherence to
receipt of care within the equal-access military health care
system. These factors make the CPDR multicenter national
database an excellent resource in which to examine racial
patterns in CaP outcomes.
4.2. Future Directions. Further investigation is needed to
explore why younger black men with higher-risk disease are
opting for AS for initial treatment. Furthermore, we need a
betterunderstandingofwhatinﬂuencessecondarytreatment
decisions. In spite of disparities in secondary treatment
choices, study outcomes among patients receiving AS for
primary treatment did not diﬀer across race, despite racial
diﬀerences in baseline clinical risk characteristics.
Subsequent work in this expanding cohort of men will
examine the speciﬁc patterns of health care delivery and
use with regard to CaP. Studies of this nature will allow us,
over time, to better understand how military health care
beneﬁciaries are diagnosed and treated in our equal-access
system after a CaP diagnosis.
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